Otsuka Korea to launch novel antipsychotic agent "Abilify" in early next year

Published: 2003-10-29 07:00:00

Updated: 2003-10-29 07:00:00

Otsuka Korea said it is planning to launch Abilify (aripiprazole), a new antipsychotic agent called a dopamine system stabilizer (DSS) that has a unique mechanism of action, in Korea during the early next years after the obtainment of its import license from the Korea Food and Drug Administration...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK